« Previous AbstractBreathomics--exhaled volatile organic compound analysis to detect hepatic encephalopathy: a pilot study    Next AbstractNoninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine »

Dig Liver Dis

Title:		Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD)
Author(s):		Arasaradnam RP; McFarlane M; Daulton E; Skinner J; O'Connell N; Wurie S; Chambers S; Nwokolo C; Bardhan K; Savage R; Covington J;
Address:		"Department of Gastroenterology, University Hospital Coventry & Warwickshire, Coventry, United Kingdom; Clinical Sciences Research Institute, University of Warwick, Coventry, United Kingdom. Electronic address: r.arasaradnam@warwick.ac.uk. Department of Gastroenterology, University Hospital Coventry & Warwickshire, Coventry, United Kingdom. School of Engineering, University of Warwick, Coventry, United Kingdom. Centre for Complexity Science, University of Warwick, United Kingdom. Department of Gastroenterology, Rotherham General Hospital, Rotherham, United Kingdom. Centre for Complexity Science, University of Warwick, United Kingdom; Warwick Medical School, University of Warwick, Coventry, United Kingdom"
Journal Title:		Dig Liver Dis
Year:		2016
Volume:		20151122
Issue:		2
Page Number:		148 - 153
DOI:		10.1016/j.dld.2015.10.013
ISSN/ISBN:		1878-3562 (Electronic) 1590-8658 (Linking)
Abstract:		"INTRODUCTION: Early inflammatory bowel disease (IBD) diagnosis remains a clinical challenge. Volatile organic compounds (VOCs) have shown distinct patterns in Crohn's disease (CD) and ulcerative colitis (UC). VOC production, reflecting gut fermentome metabolites, is perturbed in IBD. VOC sampling is non-invasive, with various compounds identified from faecal, breath and urine samples. This study aimed to determine if FAIMS (field asymmetric ion mobility spectroscopy) analysis of exhaled VOCs could distinguish IBD from controls. METHODS: Seventy-six subjects were recruited, 54 established IBD (25 CD, 29 UC) and 22 healthy controls. End expiratory breath was captured using a Warwick device and analysed by FAIMS. Data were pre-processed using wavelet transformation, and classification performed in a 10-fold cross-validation. Feature selection was performed using Wilcoxon rank sum test, and sparse logistic regression gave class predictions, to calculate sensitivity and specificity. RESULTS: FAIMS breath VOC analysis showed clear separation of IBD from controls, sensitivity: 0.74 (0.65-0.82), specificity: 0.75 (0.53-0.90), AUROC: 0.82 (0.74-0.89), p-value 6.2x10(-7). IBD subgroup analysis distinguished UC from CD: sensitivity of 0.67 (0.54-0.79), specificity: 0.67 (0.54-0.79), AUROC: 0.70 (0.60-0.80), p-value 9.23x10(-4). CONCLUSION: This confirms the utility of exhaled VOC analysis to distinguish IBD from healthy controls, and UC from CD. It conforms to other studies using different technology, whilst affirming exhaled VOCs as biomarkers for diagnosing IBD"
Keywords:		"Adult Biomarkers Breath Tests Case-Control Studies Colitis, Ulcerative/*diagnosis Crohn Disease/*diagnosis Female *Fermentation *Gastrointestinal Microbiome Humans Inflammatory Bowel Diseases/diagnosis Male Middle Aged Prospective Studies Sensitivity and;"
Notes:		"MedlineArasaradnam, Ramesh P McFarlane, Michael Daulton, Emma Skinner, Jim O'Connell, Nicola Wurie, Subiatu Chambers, Samantha Nwokolo, Chuka Bardhan, Karna Savage, Richard Covington, James eng Netherlands 2015/12/20 Dig Liver Dis. 2016 Feb; 48(2):148-53. doi: 10.1016/j.dld.2015.10.013. Epub 2015 Nov 22"